Does EXEL pay a dividend and is it safe?

Exelixis Inc. (EXEL) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / EXEL / dividends

HALO (75) NBIX (73) BNTX (52) TECH (72) ⌘ Pro Terminal →

Exelixis Inc. (EXEL) Dividend Safety Gauge & 10-Year DRIP Compounder

$70.13 +1.07% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $70.43

Exelixis Inc. (EXEL) earns a Roarable Rating of A (Strong Buy) with 91/100 RQD Confidence. High-quality cash engine (96.0% gross margin, 35% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE A • STRONG BUY Cap $16.93B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on EXEL Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is EXEL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Exelixis Inc. (NASDAQ: EXEL) is rated A (Strong Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 91/100 at a spot price of $70.13 (+1.07% 1D, market cap $16.93B). Pillar breakdown: Fundamental Cash Engine 20/20, Institutional 13F & Options Flow 19/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 18/20, and Executive Insider Alignment 16/20. Across 1015 tracked Health Care issuers, EXEL ranks #1 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does EXEL compare to HALO and NBIX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), EXEL carries a Roarable A (91/100 RQD), trailing P/E of 21.0x, gross margin of 96.0%, and ROIC of 35.1%. By comparison, HALO (Halozyme Therapeutics Inc.) holds a B grade (75/100 RQD, P/E 47.0x, ROIC 18.0%, cap $14.86B) and NBIX (Neurocrine Biosciences Inc.) posts a B grade (73/100 RQD, P/E 31.1x, ROIC 15.7%, cap $14.85B). Among the 5-stock peer group, EXEL leads on earnings multiple (21.0x) while EXEL leads on capital efficiency (35.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for EXEL?

▼

Per EXEL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-01-02, CIK 0000939767), Exelixis Inc. generated $2.32B in revenue (+7.0% YoY), $782.6M in net income, and $875.8M in free cash flow against $2.84B in total assets and $307.4M in total debt. Key quantitative strengths: Strong cash generator (96.0% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $70.43 (+0.43%)🧬 Cannibal Buyback (-2.36% YoY Shares)⚙️ Cash Engine: 20/20 (A+) • 37.7% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 91/100 (A) historically ranked in the Top 4% of excess returns over the next 90 days (+10.0% avg 90D alpha vs SPY • 74.8% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSTRONG BUY • A

3-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw A+ · Rk A

Each axis scored 0–20

12M PRICE TARGET CONE+14.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EXEL)Realized 20D OHLCV Swing Band: ±5.7%

Deterministic 5-Pillar Attribution (91/100 Composite)

🔍 WHY EXEL SCORES 91/100 (A) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+20/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 37.7% FCF Margin ($875.8M FCF) & 96.4% Gross Margin

▲ #2 Bullish Driver: Whale & Options Positioning+19/20 pts (21% of score)

20D Institutional Volume Accumulation (±5.7% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution16/20 pts (-4 pt drag)

Cannibal Buyback (-2.36% YoY Shares) & executive Form 4 sales trim 4 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade A$60.99+5.9% Next Q

Q2 (-2Q)

Grade A$64.58+2.6% Next Q

Q3 (-1Q)

Grade A$66.28+5.8% Next Q

Current

Grade A$70.13+10% Hist 90D α

Trajectory: A (83) → A (91)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the EXEL Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 91/100 (A) score, EXEL faces multiple-compression risk if 21.0x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.36% YoY Shares) — any gross margin slip below 93.9% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($60.12) or 200D SMA ($51.26) invalidates the momentum regime and cuts Target Base ($80.54) toward Bear Floor ($57.51).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $EXEL• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “EXEL Beats Next Quarter EPS Consensus (Jan 1, 2027) & Holds Above 200D SMA”

YES 89%NO 11%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.7% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,408

Est. Year-10 Shareholder Yield: $313/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.2K

Yr 2

$11.8K

Yr 3

$12.5K

Yr 4

$13.2K

Yr 5

$13.9K

Yr 6

$14.7K

Yr 7

$15.6K

Yr 8

$16.5K

Yr 9

$17.4K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Cash-Flow & Quality Compounder Desk

Cash-Fortress Compounders: Auditing Free Cash Flow & Yield Safety in EXEL & A-Rated Leaders

✓12-month Bull/Base/Bear fair-value walkthrough on EXEL and its top sector peer
✓Top Roarable A-Rated cash compounders with verified executive & 13F accumulation
✓Includes nightly RQD rating-change & forensic signal email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

EXEL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +58.77%▲ ASCENDING CHANNEL

2026-11-03O $66.20H $70.13L $66.20C $70.13VOL 5.07M

RES: $72.62SUP: $52.18SMA50: $60.12SMA200: $51.26

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

EXEL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 EXEL Butterfly Map → + Track EXEL →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

14.6%/yr Implied 5Y Growth

vs. +7.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on EXEL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for EXEL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for EXEL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EXEL)

Health Care Rank #1 of 1015 ⚔️ HALO vs EXEL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (EXEL vs. HALO, NBIX, BNTX, TECH)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Exelixis Inc. (EXEL) ranks #1 by composite RQD confidence (91/100, grade A) and #75 by equity capitalization ($16.93B). Within this direct 5-issuer industry benchmark cohort, EXEL leads on earnings valuation at 21.0x trailing P/E, while EXEL leads on capital efficiency and profitability with 35.1% ROIC and 96.0% gross margin. EXEL currently leads its immediate peer cohort in composite quantitative strength at 91/100 (A).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
EXEL ACTIVE Exelixis Inc.	A	91/100	21.0x	96.0%	35.1%	+1.07%	$16.93B	Benchmark Subject
HALO Halozyme Therapeutics Inc.	B	75/100	47.0x	83.6%	18.0%	-1.50%	$14.86B	/halo-vs-exel →
NBIX Neurocrine Biosciences Inc.	B	73/100	31.1x	96.0%	15.7%	-0.51%	$14.85B	/nbix-vs-exel →
BNTX BioNTech SE	D+	52/100	32.8x	—	9.9%	-0.73%	$22.15B	/bntx-vs-exel →
TECH Bio-Techne Corp	B	72/100	155.3x	64.8%	3.4%	+0.01%	$11.39B	/tech-vs-exel →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-01-02 • CIK 0000939767 ↗

In its most recent audited fiscal period (FY2025, filed 2026-01-02), Exelixis Inc. (EXEL) reported GAAP revenue of $2.32B (+7.0% vs. FY2024 revenue of $2.17B , and +26.8% cumulative change since FY2023) , GAAP net income of $782.6M, operating cash flow of $884.3M, and free cash flow of $875.8M (+30.4% YoY). On the balance sheet, EXEL closed FY2025 with $2.84B in total assets against $307.4M in total debt (Altman Z-Score: 16.64, Piotroski F-Score: 9/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2026-01-02	$2.32B	$782.6M	$884.3M	$875.8M	$2.84B	$307.4M
FY2024 (FY)	2025-01-03	$2.17B	$521.3M	$700.0M	$671.5M	$2.95B	$316.6M
FY2023 (FY)	2024-12-29	$1.83B	$207.8M	$333.3M	$251.0M	$9.02B	$2.11B

3. EXEL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is EXEL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does EXEL compare to HALO and NBIX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for EXEL?

Where is EXEL trading relative to its 50-day, 200-day, and 52-week technical levels?

EXEL last traded at $70.13 (+1.07% on volume of 5,591,240 shares), positioning the stock +16.65% above its 50-day simple moving average ($60.12) and +36.81% above its 200-day simple moving average ($51.26). Across its 52-week range of $36.00 to $72.10, EXEL sits at the 94.5% percentile with a 14-day RSI of 70.9 (OVERBOUGHT (>70)) and an implied next-earnings move of ±5.7% ($66.13 to $74.13).

Direct Sub-Reports: EXEL RQD Cockpit EXEL 12M Forecast EXEL Earnings & Move EXEL Dividends & DRIP EXEL Insiders & 13F EXEL Whale Options EXEL Profit Sankey EXEL News & Why

ROARABLE RATING BRIEF • RQD 91/100 (A) ✓ SEC XBRL & RQD VERIFIED

EXEL — Exelixis Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2026-01-02

1. Roarable Rating Brief: What This Means to a Prospective Investor

Exelixis Inc. (EXEL) earns a live Roarable RQD composite score of 91/100, corresponding to a A letter grade (Roarable Strong Buy) at a spot price of $70.13 (+1.07% 1D, market capitalization $16.93B).

Fundamental Cash Engine (20/20): Anchored by return on invested capital (ROIC) of 35.1%, gross margin of 96.0%, operating margin of 37.6%, and free cash flow yield of 5.34%.
Whale 13F & Options Flow (19/20) + Insider Conviction (16/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (18/20) + Forensic Balance Sheet (18/20): Incorporates a 0.96x equity beta, Altman Z-Score of 16.64, Piotroski F-Score of 9/9, and Debt/Equity of 0.13x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Exelixis Inc. (EXEL) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. It carries a market capitalization of $16.4B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2026-01-02), Exelixis Inc. (EXEL) reported $2.32B in annual revenue (up from $2.17B in FY2024, +7.0% YoY) and $782.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.83B revenue, $207.8M net income) through FY2025, EXEL scaled operating cash flow to $884.3M and free cash flow to $875.8M, backed by $2.84B in total assets against $307.4M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (A • RQD 91/100): Strong cash generator (96.0% gross margin)—profits are backed by real money, not accounting tricks. Big institutional funds and options desks are actively positioning on the bullish side. With Fundamental Cash Engine at 20/20 and Institutional Whale Flow at 19/20, sustained execution supports upside toward the upper end of the $36.00 – $72.10 52-week range.
🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 21.0x trailing P/E and 18.4x EV/EBITDA against 37.6% operating margins and a 0.96x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), EXEL carries a macro regime beta of 0.96 and gross margin of 96.0%.

Key Question #1: Can EXEL sustain or expand its 37.6% operating margin and 35.1% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $2.32B and free cash flow of $875.8M, how will capital allocation balance growth reinvestment against $307.4M in total debt?
Key Question #3: How sensitive is EXEL's 19.5x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.96x)?

EXEL Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Exelixis Inc. (EXEL) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to EXEL Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 1d ago

Exelixis (EXEL) Stock May Be Undervalued As Earnings Stay In Focus

Yahoo Finance report covering Exelixis Inc. (EXEL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Trefis • 1d ago

Is Exelixis Stock Engineered To Make You Money?

Trefis report covering Exelixis Inc. (EXEL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ChartMill • 1d ago

Exelixis (NASDAQ:EXEL) Flashes Strong Technicals and Tight Breakout Setup

ChartMill report covering Exelixis Inc. (EXEL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Investing.com • 1d ago

Citizens raises Exelixis stock price target to $65 on ESMO data

Investing.com report covering Exelixis Inc. (EXEL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH The Motley Fool • 1d ago

Forget the FDA Delay: 3 Reasons Exelixis Is Still a Buy

The Motley Fool report covering Exelixis Inc. (EXEL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 1d ago

Exelixis (EXEL) Stock May Be A Bargain Despite Its 223% Run

Yahoo Finance report covering Exelixis Inc. (EXEL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

What Exelixis (EXEL) Said on Its Q3 Earnings Call

TradingView report covering Exelixis Inc. (EXEL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Exelixis (NasdaqGS:EXEL) Stock Forecast & Analyst Predictions

Simply Wall St report covering Exelixis Inc. (EXEL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

EXEL Bull vs. Bear Conversation Board — What's Your Call at $70.13?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON EXEL 🐻 33% BEARISH CONVICTION

BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $86.04 (+24.0%)

📌 Pinned Debate

Per the RQD rating, a 20/20 cash-engine pillar with 35.1% ROIC and a 5.34% FCF yield backs a Strong Buy verdict.

Here is why I am bullish on EXEL here at $69.39: Per the RQD rating, a 20/20 cash-engine pillar with 35.1% ROIC and a 5.34% FCF yield backs a Strong Buy verdict.. Compare EXEL's 37.6% operating margin and 35.1% ROIC against the rest of Biotechnology: Biological Products (No Diagnostic Substances). As long as cash conversion holds up, dips toward $65.92 are getting bought.

EarningsSniper 🐂 BULL

Both sides have a point here — EXEL's 18/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $54.12 (-22.0%)

Spot @ $69.39

At 21 trailing P/E and 18.4 EV/EBITDA, the stock already prices in substantial earnings growth, and a red risk-watch item cites an FDA

Careful chasing EXEL at $69.39. At 21 trailing P/E and 18.4 EV/EBITDA, the stock already prices in substantial earnings growth, and a red risk-watch item cites an FDA delay.. Gross margin is 96.0%, but operating margin is 37.6%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $54.12 on multiple compression.